Rucaparib shows clinical benefit in pancreatic cancer patients with BRCA mutation

Newsfeed Image, Light Gray Text On Dark Gray Background

The targeted therapy rucaparib, which has demonstrated robust clinical activity in ovarian cancer patients with a BRCA mutation, also showed promise in previously treated pancreatic cancer patients with the mutation.